48.36
전일 마감가:
$48.88
열려 있는:
$47.92
하루 거래량:
1.21M
Relative Volume:
1.41
시가총액:
$3.03B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
18.46
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
-7.94%
1개월 성능:
+28.65%
6개월 성능:
+7.47%
1년 성능:
+67.16%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
48.36 | 3.03B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-06 | 개시 | BMO Capital Markets | Outperform |
2024-12-06 | 개시 | Goldman | Neutral |
2024-11-05 | 개시 | Wedbush | Outperform |
2024-09-24 | 개시 | TD Cowen | Buy |
2024-09-09 | 개시 | Truist | Buy |
2023-10-30 | 개시 | CapitalOne | Overweight |
2023-05-25 | 재개 | Jefferies | Buy |
2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
2022-02-11 | 개시 | BTIG Research | Buy |
2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
2021-05-24 | 개시 | Northland Capital | Outperform |
2021-01-06 | 개시 | JP Morgan | Overweight |
2020-12-16 | 개시 | Piper Sandler | Overweight |
2020-09-18 | 재확인 | H.C. Wainwright | Buy |
2020-07-15 | 개시 | Jefferies | Buy |
2020-05-18 | 재확인 | H.C. Wainwright | Buy |
2019-07-08 | 개시 | H.C. Wainwright | Buy |
2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
2018-12-06 | 개시 | Nomura | Buy |
2018-01-29 | 개시 | Stifel | Buy |
2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance
Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia
BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):